Treatment of Tuberculosis GuidelinesDate:
04/2010 DescriptionThese guidelines are the fourth edition from the World Health Organization and provide information on tuberculosis treatment and control. These guidelines provide some key recommendations: 1) The recommendation now suggest discontinuation of the regimen based on just 2 months of rifampicin (2HRZE/6HE) and change to the regimen based on a full 6 months of rifampicin (2HRZE/4HR); 2) They confirm prior WHO recommendations for drug susceptibility testing (DST) at the start of therapy for all previously treated patients. Finding and treating multidrug-resistant TB (MDR-TB) in previously treated patients will help to improve the very poor outcomes in these patients. The retreatment regimen with first-line drugs (formerly called "Category 2" regimen) is ineffective in MDR-TB; it is therefore critical to detect MDR-TB promptly so that an effective regimen can be started; 3) Detecting MDR-TB will require expansion of DST capacity within the context of country-specific, comprehensive plans for laboratory strengthening. 4) Diagnosing MDR-TB cases among previously treated patients and providing effective treatment will greatly help in halting the spread of MDR-TB. This edition also addresses the prevention of acquired MDR-TB. Source OrganizationWorld Health Organization Find Similar Resources
Search for similar items in the following categories:
|
